Axsome Therapeutics AXSM Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's royalty — revenue?
- Axsome Therapeutics (AXSM) reported royalty — revenue of $4.07M in Q1 2026.
- How has Axsome Therapeutics's royalty — revenue changed year-over-year?
- Axsome Therapeutics's royalty — revenue increased by 268.6% year-over-year, from $1.11M to $4.07M.
- What does royalty — revenue mean?
- Revenue earned from licensing intellectual property to other companies in exchange for royalty payments.
- How do you interpret royalty — revenue?
- An increase indicates growing market adoption of licensed products or successful expansion of the company's licensing portfolio, while a decrease may suggest declining sales of licensed assets or the expiration of royalty agreements.
- How does royalty — revenue compare across companies?
- Comparable to royalty revenue streams reported by other biopharmaceutical companies that license out proprietary drug candidates or technology platforms to larger commercial partners.